Patent SG-11201809627Q-A (SG)
Title: Anti pd-1 and anti-lag3 antibodies for cancer treatment
Inventor: ZETTL MARKUS
IPC: C07K16/28
Filed: 2017-05-17
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 23 November 2017 (23.11.2017) WIPO PCT omit VIII Hot 0 mu 110 VIII Imo oimIE (10) International Publication Number WO 2017/198741 Al (51) International Patent Classification: C07K 16/28 (2006.01) A61K 39/00 (2006.01) (21) International Application Number: PCT/EP2017/061901 (22) International Filing Date: 17 May 2017 (17.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: EP16170174.3 18 May 2016 (18.05.2016) EP (71) Applicant: BOEHRINGER INGELHEIM INTER- NATIONAL GMBH [DE/DE]; Binger Strasse 173, 55216 Ingelheim am Rhein (DE). (72) Inventors: ZETTL, Markus; Boehringer Ingelheim GmbH / Corporate Patents Binger Strasse 173, 55216 Ingel- heim am Rhein (DE). LORENZ, Ivo; c/o VP, IP, Legal / Boehringer Ingelheim USA Corp. 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT, Connecticut 06877-0368 (US). SCHAAF, Otmar; Boehringer Ingelheim GmbH / Corporate Patents Binger Strasse 173, 55216 Ingelheim am Rhein (DE). WURM, Melanie; Boehringer Ingelheim GmbH / Corporate Patents Binger Strasse 173, 55216 In- gelheim am Rhein (DE). FORTIN, Jean-Francois; 639, Robert-Elie Street, Apt 904 Laval, Quebec, Laval, H7N 3Y9 (CA). BRODEUR, Scott; 3553 N. Sugan Road New Hope, New Hope, PA 18938 (US). CANADA, Keith A.; 24 Equinox Lane Freehold, Freehold, NJ 07728 (US). CHLEWICKI, Lukasz; 5803 Peaking Fox Drive Indi- anapolis, Indianapolis, IN 46237 (US). (72) Inventor: DAVIDSON, Walter Carroll (deceased). (72) Inventors: GUPTA, Pankaj; c/o VP, IP, Legal / Boehringer Ingelheim USA Corp. 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT, Connecticut 06877-0368 (US). GUPTA, Priyanka; c/o VP, IP, Legal / Boehringer Ingelheim USA Corp. 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT, Connecticut 06877-0368 (US). PEREZ, Rocio K.; c/o VP, IP, Legal / Boehringer Ingelheim USA Corp. 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT, Connecticut 06877-0368 (US). WOSKA Jr., Joseph Robert; c/o VP, IP, Legal / Boehringer Ingelheim USA Corp. 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT, Connecticut 06877-0368 (US). XIAO, Haiguang; c/o VP, IP, Legal / Boehringer Ingelheim USA Corp. 900 Ridge- bury Road, P.O. Box 368, Ridgefield, CT, Connecticut 1-1 71' N 06877-0368 (US). YANG, Danlin; c/o VP, IP, Legal / Boehringer Ingelheim USA Corp. 900 Ridgebury Road, GC 1-1 P.O. Box 368, Ridgefield, CT, Connecticut 06877-0368 (US). (74) Agent: SIMON, Elke et al.; Boehringer Ingelheim GmbH, Corporate Patents, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) N O (57) : The disclosure relates to anti-PD1 and anti-LAG3 antibody molecules. Compositions comprising such antibody mole- 0 cules, in particular for therapeutic purposes in the field of cancer diseases are also claimed. (54) Title: ANTI PD-1 AND ANTI-LAG3 ANTIBODIES FOR CANCER TREATMENT